StockData
Acrivon Therapeutics, Inc. logo

Acrivon Therapeutics, Inc. (ACRV) company profile

ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$1.43−0.03 (-2.05%)

Close on Nov 17, 2026Market cap $61.28MP/E –Yield –

About Acrivon Therapeutics

Pharmaceutical Preparations, SIC 2834

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision oncology medicines. The company utilizes its proprietary Generative Phosphoproteomics Acrivon Predictive Precision Proteomics (AP3) platform to quantify drug-regulated pathway activity levels inside intact tumor cells in an unbiased manner. Its core pipeline includes ACR-368 (prexasertib), a targeted CHK1 and CHK2 inhibitor undergoing Phase 2b clinical trials for indications such as endometrial cancer, and ACR-2316, a selective dual WEE1/PKMYT1 inhibitor in Phase 1 evaluation. In addition, Acrivon advances ACR-6840 targeting CDK11. The company uses drug-tailored OncoSignature companion diagnostic tests to match targeted therapies with specific patients likely to respond.

The company operates a certified Clinical Laboratory Improvement Amendments (CLIA) laboratory to process patient samples and perform diagnostic testing in-house. Acrivon is headquartered in Watertown, Massachusetts, where it maintains principal executive offices. The company also conducts operations and leases facility space in Sweden.

Summary of the business section of Acrivon Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Acrivon Therapeutics, Inc.
Founded
2018
Headquarters
Watertown, MA
Address
480 Arsenal Way, Suite 100 02472
Phone
(617) 207-8979
Employees
74, Dec 31, 2025
Industry
Pharmaceutical Preparations
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Boston, Massachusetts

Stock & identifiers

Ticker
ACRV
Exchange
Nasdaq
IPO date
Nov 16, 2022
Shares outstanding
43M, Aug 7, 2026
Public float
$20.40M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1781174
CUSIP
004890109
ISIN
US0048901096
FIGI
BBG011RWR2Q4
Share class FIGI
BBG011RWR2R3
EIN
82-5125532

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Kristina MassonEVP - Business Operations, Director2,629,947
Peter Blume-JensenPresident and CEO, Director2,615,911
Mary MillerChief Legal Officer81,202
Michaela LevinChief Business Officer30,000
Eric DevroeChief Operating Officer146,349
Katharine PetersonChief Accounting Officer18,033
Erick GamelinChief Development Officer52,592
Adam D. LevyChief Financial Officer66,008
Mansoor Raza MirzaChief Medical Officer38,817
Jean-Marie CuillerotChief Medical Officer–
Rasmus Holm-JorgensenChief Financial Officer26,088
Santhosh PalaniDirector9,366
Rajeev M. ShahDirector–
Peter KolchinskyDirector–
Ra Capital Management, L.P.Director–
RA Capital Nexus Fund II, L.P.Director9,366
Charles M. BaumDirector9,366
Derek DiRoccoDirector9,366
Capital Healthcare Fund LP RADirector7,914,206
Sharon ShachamDirector9,366
Michael John TomsicekDirector9,366
Ivana Magovcevic-LiebischDirector9,366

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Peter Blume-Jensen
Chief Executive Officer, President and Director
$709.89K$1.59M$410.40K$6.00K$2.72M+36%
Kristina Masson
Executive Vice President, Business Operations, Director
$594.47K$573.21K$251.25K$6.00K$1.42M+19%
Eric Devroe
Chief Operating Officer
$528.75K$573.21K$250.05K$6.00K$1.36M+18%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 16, 2022
Offer price
$12.50
Securities offered
7,550,000
Gross proceeds
$94.38M
Exchange
Nasdaq
First trading day
Nov 15, 2022
First-day close
$16.64+33.1%
Lock-up ends (est.)
May 14, 2023

“Per Share Total Initial public offering price $12.50 $94,375,000 Underwriting discounts and commissions (1) $0.875 $6,606,250 Proceeds, before expenses, to us $11.625 $87,768,750 (1) We refer you to “Underwriting” for additional information regarding total underwriter compensation.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 74 full-time employees and two part-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?